tetano
Editor, Senior Moderator
Microorganisms
. 2021 Jan 13;9(1):E165.
doi: 10.3390/microorganisms9010165.
Development of Coronavirus Treatments Using Neutralizing Antibodies
Saman Fouladirad[SUP] 1 [/SUP], Horacio Bach[SUP] 1 2 [/SUP]
Affiliations
Abstract
The Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus SARS-CoV-2, was first reported in December 2019 in Wuhan, Hubei province, China. This virus has led to 61.8 million cases worldwide being reported as of December 1st, 2020. Currently, there are no definite approved therapies endorsed by the World Health Organization for COVID-19, focusing only on supportive care. Treatment centers around symptom management, including oxygen therapy or invasive mechanical ventilation. Immunotherapy has the potential to play a role in the treatment of SARS-CoV-2. Monoclonal antibodies (mAbs), in particular, is a relatively new approach in the world of infectious diseases and has the benefit of overcoming challenges with serum therapy and intravenous immunoglobulins preparations. Here, we reviewed the articles published in PubMed with the purpose of summarizing the currently available evidence for the use of neutralizing antibodies as a potential treatment for coronaviruses. Studies reporting in vivo results were summarized and analyzed. Despite promising data from some studies, none of them progressed to clinical trials. It is expected that neutralizing antibodies might offer an alternative for COVID-19 treatment. Thus, there is a need for randomized trials to understand the potential use of this treatment.
Keywords: MERS-CoV; SARS-CoV; SARS-CoV-2; antibody treatment; coronavirus; neutralizing antibodies.
. 2021 Jan 13;9(1):E165.
doi: 10.3390/microorganisms9010165.
Development of Coronavirus Treatments Using Neutralizing Antibodies
Saman Fouladirad[SUP] 1 [/SUP], Horacio Bach[SUP] 1 2 [/SUP]
Affiliations
- PMID: 33451069
- DOI: 10.3390/microorganisms9010165
Abstract
The Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus SARS-CoV-2, was first reported in December 2019 in Wuhan, Hubei province, China. This virus has led to 61.8 million cases worldwide being reported as of December 1st, 2020. Currently, there are no definite approved therapies endorsed by the World Health Organization for COVID-19, focusing only on supportive care. Treatment centers around symptom management, including oxygen therapy or invasive mechanical ventilation. Immunotherapy has the potential to play a role in the treatment of SARS-CoV-2. Monoclonal antibodies (mAbs), in particular, is a relatively new approach in the world of infectious diseases and has the benefit of overcoming challenges with serum therapy and intravenous immunoglobulins preparations. Here, we reviewed the articles published in PubMed with the purpose of summarizing the currently available evidence for the use of neutralizing antibodies as a potential treatment for coronaviruses. Studies reporting in vivo results were summarized and analyzed. Despite promising data from some studies, none of them progressed to clinical trials. It is expected that neutralizing antibodies might offer an alternative for COVID-19 treatment. Thus, there is a need for randomized trials to understand the potential use of this treatment.
Keywords: MERS-CoV; SARS-CoV; SARS-CoV-2; antibody treatment; coronavirus; neutralizing antibodies.